Cleveland BioLabs, Inc. CBLI

Cleveland BioLabs, Inc. Revenue 2011-2026 | CBLI

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Cleveland BioLabs, Inc.

2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
263 K	1.11 M	1.14 M	1.95 M	3.52 M	2.71 M	3.7 M	8.49 M	3.57 M	8.79 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
8.79 M	263 K	3.52 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
BioNTech SE BNTX	482 M	$ 91.28	0.11 %	$ 27.2 B	Germany
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Alnylam Pharmaceuticals ALNY	3.71 B	$ 330.34	3.6 %	$ 43.3 B	USA
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Evogene Ltd. EVGN	8.51 M	$ 0.79	1.22 %	$ 27.9 M	Israel
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
argenx SE ARGX	36.4 M	$ 748.25	0.25 %	$ 25 B	Niderland
Завод ДИОД DIOD	517 M	-	-	-	Russia
Фармсинтез LIFE	372 M	-	-	-	Russia
Aptorum Group Limited APM	912 K	$ 0.89	-4.33 %	$ 4.85 M	China
Applied Therapeutics APLT	9.99 M	-	-	$ 8.42 M	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
Teligent, Inc. TLGT	45.3 M	-	-13.85 %	$ 16.1 M	USA
AbbVie ABBV	16.6 B	$ 206.69	-1.01 %	$ 366 B	USA
Aquestive Therapeutics AQST	44.5 M	$ 4.09	-0.97 %	$ 437 M	USA
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Viela Bio, Inc. VIE	11.7 M	-	-	$ 2.91 B	USA
AbCellera Biologics ABCL	75.1 M	$ 3.39	-3.69 %	$ 1.01 B	Canada
Arcturus Therapeutics Holdings ARCT	82 M	$ 8.22	2.37 %	$ 225 M	Israel
Ardelyx ARDX	407 M	$ 5.97	0.51 %	$ 1.44 B	USA
Genmab A/S GMAB	10.1 B	$ 27.75	0.91 %	$ 17.6 B	Danmark
Cerevel Therapeutics Holdings CERE	2.72 M	-	-	$ 7.29 B	USA
Grifols, S.A. GRFS	7.21 B	$ 8.23	-0.12 %	$ 6.83 B	Spain
Akebia Therapeutics AKBA	236 M	$ 1.32	-4.35 %	$ 339 M	USA